Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05237271 · ClinicalTrials.gov registry record · NA
Clinical Utility Trial for the SomaLogic CVD-T2D Test
A NA study, sponsored by Qure Healthcare.
- Completed
- Registry status
- NA
- Development phase
- 251
- Enrollment target
NCT05237271 is a NA study that has completed, run by Qure Healthcare. The registered enrollment target is 251 participants.
The verdict
NCT05237271, a NA study, has completed, sponsored by Qure Healthcare.
- COMPLETED
- Registry status
- NA
- Development phase
- 251 participants
- Enrollment target
Study Summary
QURE will use its CPV technology in a randomized controlled trial to measure how SomaLogic's diagnostic test (the Cardiovascular Disease in Type 2 Diabetes) changes clinical practice and improves patient outcomes.
Interventions
- OTHER Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)
- OTHER Educational Materials on the CVD-T2D and Bundled Metabolic Panel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2022-08-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05237271
The ClinicalTrials.gov registry entry for NCT05237271 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qure Healthcare, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D) is the first listed.
NCT05237271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05237271 about?
NCT05237271 is a clinical study titled "Clinical Utility Trial for the SomaLogic CVD-T2D Test". QURE will use its CPV technology in a randomized controlled trial to measure how SomaLogic's diagnostic test (the Cardiovascular Disease in Type 2 Diabetes) changes clinical practice and improves patient outcomes.
What is the current status of trial NCT05237271?
This trial is currently completed. It is a NA study. The enrollment target is 251 participants. The study started on 2022-03-15. Estimated completion is 2022-08-15.
What interventions are being tested in trial NCT05237271?
The interventions under investigation include: Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D) (OTHER), Educational Materials on the CVD-T2D and Bundled Metabolic Panel (OTHER).
Who is sponsoring clinical trial NCT05237271?
This trial is sponsored by Qure Healthcare, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.